Related Experiment Video

Updated: Jul 20, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

[Importance of vascular aspects in Alzheimer's disease]

Hiroyuki Arai1

  • 1Department of Geriatrics and Gerontology, Center for Asian Traditional Medicine, Tohoku University Graduate School of Medicine.

Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
|August 30, 2006
PubMed

Insights

High homocysteine levels are linked to stroke and Alzheimer's disease (AD). These elevated levels may also increase the risk of falls and aspiration pneumonia in AD patients due to brain lesions.

Area of Science:

  • Neurology
  • Geriatrics
  • Vascular Medicine

Context:

  • Elevated plasma homocysteine is linked to atherosclerotic vascular disorders and neurodegenerative diseases like Alzheimer's disease (AD).
  • Hyperhomocysteinemia is associated with silent brain infarctions and white matter lesions in the elderly.
  • Ischemic cerebrovascular lesions are frequently observed in AD patients.

Purpose:

  • To explore the association between cerebrovascular lesions, hyperhomocysteinemia, and complications in Alzheimer's disease patients.
  • To investigate the role of specific lesion types (basal ganglia infarcts, white matter lesions) in functional impairments.

Summary:

  • Elevated homocysteine is a risk factor for stroke and Alzheimer's disease (AD).
  • Silent brain infarctions and white matter lesions, often found in AD patients, are linked to hyperhomocysteinemia.
  • Basal ganglia infarcts impair swallowing, increasing aspiration pneumonia risk in AD.
  • Periventricular white matter lesions correlate with an increased risk of falls in AD patients.

Impact:

  • Understanding these associations can inform preventative strategies for AD complications.
  • Highlights the importance of managing homocysteine levels in elderly populations at risk for cognitive decline and vascular issues.
  • Provides insights into the multifactorial nature of AD progression and associated morbidities.

More Related Videos

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption10:36

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption

Published on: June 20, 2017

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...